Aliases & Classifications for Leukemia

Summaries for Leukemia

MedlinePlus : 41 leukemia is cancer of the white blood cells. white blood cells help your body fight infection. your blood cells form in your bone marrow. in leukemia, the bone marrow produces abnormal white blood cells. these cells crowd out the healthy blood cells, making it hard for blood to do its work. there are different types of leukemia, including acute lymphocytic leukemia acute myeloid leukemia chronic lymphocytic leukemia chronic myeloid leukemia leukemia can develop quickly or slowly. chronic leukemia grows slowly. in acute leukemia, the cells are very abnormal and their number increases rapidly. adults can get either type; children with leukemia most often have an acute type. some leukemias can often be cured. other types are hard to cure, but you can often control them. treatments may include chemotherapy, radiation and stem cell transplantation. even if symptoms disappear, you might need therapy to prevent a relapse. nih: national cancer institute

MalaCards based summary : Leukemia is related to leukemia, acute myeloid and adult acute lymphocytic leukemia, and has symptoms including angina pectoris, chest pain and edema. An important gene associated with Leukemia is LIF (LIF, Interleukin 6 Family Cytokine), and among its related pathways/superpathways are Pathways in cancer and NF-kappaB Signaling. The drugs Arranon and Arzerra have been mentioned in the context of this disorder. Affiliated tissues include myeloid, t cells and b cells, and related phenotypes are Increased HDAC inhibitor resistance and cellular

Disease Ontology : 12 A cancer that affects the blood or bone marrow characterized by an abnormal proliferation of blood cells.

Wikipedia : 71 Leukemia, also spelled leukaemia, is a group of cancers that usually begin in the bone marrow and result... more...

Related Diseases for Leukemia

Diseases in the Leukemia family:

Acute Leukemia Chronic Leukemia
Subacute Leukemia

Diseases related to Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1155)
id Related Disease Score Top Affiliating Genes
1 leukemia, acute myeloid 33.5 FLT3 MLF1 MPL RUNX1
2 adult acute lymphocytic leukemia 33.0 MCL1 RUNX1 TAL2
3 hemophagocytic lymphohistiocytosis 30.2 ABL1 FLT3 MPL RUNX1
4 liver disease 28.0 ABL1 ABL2 BAALC CLLU1 FLI1 FLT3
5 chronic lymphocytic leukemia 12.3
6 leukemia, acute lymphoblastic 12.3
7 myeloid leukemia 12.2
8 hairy cell leukemia 12.2
9 childhood leukemia 12.2
10 acute leukemia 12.2
11 leukemia, chronic myeloid, somatic 12.2
12 megakaryocytic leukemia 12.1
13 acute lymphocytic leukemia 12.1
14 lymphoblastic leukemia 12.1
15 adult t-cell leukemia 12.1
16 t-cell prolymphocytic leukemia 12.1
17 acute monocytic leukemia 12.1
18 mast-cell leukemia 12.1
19 leukemia, acute promyelocytic, somatic 12.1
20 atypical chronic myeloid leukemia 12.1
21 monocytic leukemia 12.1
22 prolymphocytic leukemia 12.1
23 leukemia, acute myelomonocytic, somatic, somatic 12.1
24 plasma cell leukemia 12.0
25 lymphoid leukemia 12.0
26 large granular lymphocyte leukemia 12.0
27 cytogenetically normal acute myeloid leukemia 12.0
28 acute erythroid leukemia 12.0
29 chronic leukemia 12.0
30 t-cell large granular lymphocyte leukemia 12.0
31 core binding factor acute myeloid leukemia 12.0
32 chronic eosinophilic leukemia 12.0
33 b cell prolymphocytic leukemia 12.0
34 acute myeloblastic leukemia with maturation 12.0
35 chronic neutrophilic leukemia 12.0
36 human t-cell leukemia virus type 1 11.9
37 acute myeloblastic leukemia without maturation 11.9
38 acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) 11.9
39 acute lymphoblastic leukemia, childhood 11.9
40 acute basophilic leukemia 11.9
41 familial acute myeloid leukemia with mutated cebpa 11.9
42 subacute leukemia 11.9
43 noonan syndrome-like disorder with or without juvenile myelomonocytic leukemia 11.9
44 t-cell leukemia 11.9
45 pdgfra-associated chronic eosinophilic leukemia 11.9
46 pdgfrb-associated chronic eosinophilic leukemia 11.9
47 adult acute monocytic leukemia 11.9
48 acute leukemia of ambiguous lineage 11.9
49 chronic myelomonocytic leukemia 11.9
50 natural killer cell leukemia 11.9

Comorbidity relations with Leukemia via Phenotypic Disease Network (PDN):


Acute Cystitis Deficiency Anemia
Heart Disease Leukemia, B-Cell, Chronic

Graphical network of the top 20 diseases related to Leukemia:



Diseases related to Leukemia

Symptoms & Phenotypes for Leukemia

UMLS symptoms related to Leukemia:


angina pectoris, chest pain, edema

GenomeRNAi Phenotypes related to Leukemia according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased HDAC inhibitor resistance GR00115-A-0 8.62 LIF LIFR

MGI Mouse Phenotypes related to Leukemia:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.23 ABL1 ABL2 FLI1 FLT3 LIF MCL1
2 hematopoietic system MP:0005397 10.21 MPL PBX1 PML RAF1 RUNX1 SLC20A1
3 growth/size/body region MP:0005378 10.18 TAL2 ABL1 ABL2 FLI1 FLT3 LIF
4 embryo MP:0005380 10.17 ABL1 ABL2 FLI1 LIF LIFR MCL1
5 homeostasis/metabolism MP:0005376 10.1 ABL1 ABL2 FLT3 HLF LIF LIFR
6 immune system MP:0005387 10.07 RAF1 RUNX1 SLC20A1 ABL1 FLI1 FLT3
7 mortality/aging MP:0010768 9.83 ABL1 ABL2 FLI1 FLT3 HLF LIF
8 liver/biliary system MP:0005370 9.76 LIFR PBX1 RAF1 RUNX1 SLC20A1 ABL1
9 nervous system MP:0003631 9.32 ABL1 ABL2 FLI1 HLF LIF LIFR

Drugs & Therapeutics for Leukemia

FDA approved drugs:

(show all 30)
id Drug Name Active Ingredient(s) 17 Company Approval Date
1
Arranon 17 46 NELARABINE GlaxoSmithKline Approved October 2005
2
Arzerra 17 46 OFATUMUMAB GlaxoSmithKline Approved October 2009
3
Blincyto 17 46 BLINATUMOMAB Amgen Approved December 2014
4
Bosulif 17 46 BOSUTINIB MONOHYDRATE Pfizer Approved September 2012
5
Busulfex 17 46 BUSULFAN Orphan Medical Approved February 1999
6
Campath 17 46 ALEMTUZUMAB Berlex Laboratories Approved May 2001
7
Clolar 17 46 CLOFARABINE Genzyme Approved December, 2004
8
Elitek 17 46 RASBURICASE sanofi-aventis Approved October 2009
9
Elliotts B Solution 17 CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE Orphan Medical Approved October 1996
10
Erwinaze 17 46 asparaginase Erwinia chrysanthemi Eusa Pharma Approved November of 2011
11
Gazyva 17 46 OBINUTUZUMAB Genentech Approved October of 2013
12
Gleevec 17 46 IMATINIB MESYLATE Novartis Approved May 2001
13
Iclusig 17 46 PONATINIB HYDROCHLORIDE Ariad Pharmaceuticals Approved December 2012
14
Imbruvica 17 46 IBRUTINIB Pharmacyclics Approved November of 2013/Approved February 2014
15
Intron A 17 46 INTERFERON ALFA-2B Schering-Plough Approved December 1997/ Approved December 1995/ Approved March 1997
16
Leukine 17 SARGRAMOSTIM Immunex Approved on November 24, 1995/ Approved November 1996
17
Lynparza 17 46 OLAPARIB AstraZeneca Approved December 2014
18
Marqibo 17 46 VINCRISTINE SULFATE Talon Therapeutics Approved August 2012
19
Mylotarg 17 46 GEMTUZUMAB OZOGAMICIN Wyeth Approved May 2000
20
Neupogen 17 46 FILGRASTIM Amgen Approval April 1998
21
Pomalyst 17 46 POMALIDOMIDE Celgene Approved February 2013
22
Revlimid 17 46 LENALIDOMIDE Celgene Approved June 2013
23
Rituxan 17 46 RITUXIMAB Biogen IDEC, Genentech Approved November 1997
24
Sprycel 17 46 DASATINIB Bristol-Myers Squibb Approved June 2006
25
Sutent 17 46 SUNITINIB MALATE Pfizer Approved May 2011/ Approved January 2006
26
Synribo 17 46 OMACETAXINE MEPESUCCINATE Teva Pharmaceutical Approved October 2012
27
Tasigna 17 46 NILOTINIB HYDROCHLORIDE MONOHYDRATE Novartis Approved October 2007
28
Treanda 17 46 BENDAMUSTINE HYDROCHLORIDE Cephalon Approved October 2008
29
Trisenox 17 46 ARSENIC TRIOXIDE Cell Therapeutics Approved September 2000
30
Zydelig 17 46 IDELALISIB Gilead Approved July 2014

Drugs for Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 838)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cytarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 147-94-4 6253
2
Daunorubicin Approved Phase 4,Phase 3,Phase 2,Phase 1 20830-81-3 30323
3
Idarubicin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 58957-92-9 42890
4
Mitoxantrone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 65271-80-9 4212
5
Arsenic trioxide Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 1327-53-3 518740
6
Adenosine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 58-61-7 60961
7
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
8
Pentostatin Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 53910-25-1 40926 439693
9
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 174722-31-7 10201696
10
Fludarabine Approved Phase 4,Phase 3,Phase 2,Phase 1 21679-14-1, 75607-67-9 30751
11
Vidarabine Approved Phase 4,Phase 3,Phase 2,Phase 1 24356-66-9 32326 21704
12
Asparaginase Approved Phase 4,Phase 3,Phase 2,Phase 1 9015-68-3
13
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-02-2 5743
14
Lenograstim Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 135968-09-1
15
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 1959-05-2, 59-05-2 126941
16
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 83-43-2 6741
17
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-24-8 5755
18
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 2068-78-2, 57-22-7 5978
19
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 23214-92-8 31703
20
Pegaspargase Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 130167-69-0
21
Azacitidine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 320-67-2 9444
22
Decitabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 2353-33-5 451668
23
Cladribine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 4291-63-8 20279
24
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 33419-42-0 36462
25
Teniposide Approved Phase 4,Phase 3,Phase 2 29767-20-2 34698
26
Thioguanine Approved Phase 4,Phase 3,Phase 2,Phase 1 154-42-7 2723601
27
Vindesine Approved Phase 4,Phase 3,Phase 2 59917-39-4, 53643-48-4 40839
28
Ifosfamide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 3778-73-2 3690
29
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 53-03-2 5865
30
Aprepitant Approved, Investigational Phase 4,Phase 3,Phase 2 170729-80-3 151165 6918365
31
Fosaprepitant Approved Phase 4,Phase 3,Phase 2 172673-20-0 219090
32
Acitretin Approved Phase 4 55079-83-9 6437841 5284513
33
Chlorambucil Approved Phase 4,Phase 3,Phase 2,Phase 1 305-03-3 2708
34
Topotecan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 119413-54-6, 123948-87-8 60700
35
Amphotericin B Approved, Investigational Phase 4,Phase 3,Phase 2 1397-89-3 14956 5280965
36
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 22916-47-8 4189
37
Amsacrine Approved Phase 4,Phase 3,Phase 2,Phase 1 51264-14-3 2179
38
Hydrocortisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-23-7 5754 657311
39
Dasatinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 302962-49-8 3062316
40
Aldesleukin Approved Phase 4,Phase 3,Phase 2,Phase 1 85898-30-2, 110942-02-4
41
Histamine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 75614-87-8, 51-45-6 774
42
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-61-6, 62-31-7 681
43
Oprelvekin Approved, Investigational Phase 4,Phase 2,Phase 3 145941-26-0
44
Granisetron Approved, Investigational Phase 4 109889-09-0 3510
45
Palonosetron Approved, Investigational Phase 4,Phase 2 135729-61-2, 119904-90-4, 135729-56-5 148211
46
Voriconazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 137234-62-9 71616
47
Busulfan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 55-98-1 2478
48
Thiotepa Approved Phase 4,Phase 3,Phase 2,Phase 1 52-24-4 5453
49
Cyclosporine Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 79217-60-0, 59865-13-3 5284373 6435893
50
Micafungin Approved, Investigational Phase 4,Phase 2 235114-32-6 3081921 477468

Interventional clinical trials:

(show top 50) (show all 5000)
id Name Status NCT ID Phase
1 AIDA2000 - Risk-Adapted Therapy for Patients With Acute Promyelocytic Leukemia Unknown status NCT00180128 Phase 4
2 Treatment Protocol for Relapsed Acute Promyelocytic Leukemia (APL) With Arsenic Unknown status NCT00196768 Phase 4
3 Idarubicin at Different Dosages as Induction Therapy for Newly Diagnosed Acute Myeloid Leukaemia Unknown status NCT02277847 Phase 4
4 Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia. Unknown status NCT00131313 Phase 4
5 AML1-ETO Acute Myeloid Leukemia With Fludarabine and Cytarabine Chemotherapy Unknown status NCT02024308 Phase 4
6 German Multicenter Trial for Treatment of Elderly Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Unknown status NCT00198978 Phase 4
7 Treatment Protocol of Children With Philadelphia Chromosome Negative High Risk Acute Lymphoblastic Leukemia Unknown status NCT01990807 Phase 4
8 Medical Research Council (MRC) Working Party on Leukaemia in Children UK National Acute Lymphoblastic Leukaemia (ALL) Trial: UKALL 2003 Unknown status NCT00222612 Phase 4
9 3 Anthracyclines, 2 Types of Consolidation With Different ARA-C Doses and Maintenance in Adult Acute Myeloid Leukemia Unknown status NCT01587430 Phase 4
10 Decitabine for Myelodysplastic Syndromes and Acute Myeloid Leukemia Before Allogeneic Hematopoietic Cell Transplantation Unknown status NCT01806116 Phase 4
11 German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003) Unknown status NCT00198991 Phase 4
12 Assessment Of Gh-Igf-1 Axis In Children With Chronic Myelogenous Leukemia (CML) In Remission Unknown status NCT01901666 Phase 4
13 Compliance: Role Emerges for Success in Chronic Myelogenous Leukaemia (CML): Evaluation aND Optimisation Unknown status NCT01243489 Phase 4
14 Poly(Ethylene Glycol)(PEG)-Asparaginase During Two Treatment Courses Unknown status NCT00192673 Phase 4
15 Efficacy of G-CSF-Priming in Elderly AML Patients Unknown status NCT00199147 Phase 4
16 Intensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin's Lymphoma in Adults Unknown status NCT00797810 Phase 4
17 Self-control Trial to Evaluate the Role of Aprepitant in the Prophylaxis of Post-lumbar-punture-headache (PLPH) Unknown status NCT02347878 Phase 4
18 Low-Dose (17.5 mg/Day) Acitretin: Comparable Efficacy Without the Side Effects? Unknown status NCT01228409 Phase 4
19 Study to Evaluate Nilotinib in Chronic Myelogenous Leukemia (CML) Patients With SubOptimal Response Completed NCT01043874 Phase 4
20 LAM07: Study to Analyze the Efficacy of a Risk Adapted Treatment Strategy, Including Gemtuzumab Ozogamicin (GO) During Consolidation, for Patients With Acute Myeloid Leukemia (AML) Completed NCT01041040 Phase 4
21 Observational Study in Participants With Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM) and Non-Hodgkin's Lymphoma (NHL) in Latin America Completed NCT02559583 Phase 4
22 A Study of MabThera Added to Bendamustine or Chlorambucil in Patients With Chronic Lymphocytic Leukemia (MaBLe) Completed NCT01056510 Phase 4
23 Treatment of the Acute Myeloblastic Leukaemia in Patients Over 65 Years Completed NCT00464217 Phase 4
24 Treatment of Elderly Patients (>65 Years) With Acute Lymphoblastic Leukemia Completed NCT00199095 Phase 4
25 Treatment of Relapsed Promyelocytic Leukemia With Arsenic Trioxide (ATO) Completed NCT00504764 Phase 4
26 Fludarabine, Cytarabine, Topotecan in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Completed NCT00488709 Phase 4
27 Treatment of Acute Promyelocytic Leukemia With All-Trans Retinoic Acid (ATRA) and Idarubicin (AIDA) Completed NCT00465933 Phase 4
28 Pulses of Vincristine and Dexamethasone in BFM Protocols for Children With Acute Lymphoblastic Leukemia Completed NCT00411541 Phase 4
29 PROPHYSOME: Pilot Study on Safety of a Weekly Administration of 10mg/kg of AmBisome® in Antifungal Prophylaxis Treatment of Allogeneic Stem-cell Transplantation and Acute Leukaemia Completed NCT00362544 Phase 4
30 Glivec® (Imatinib Mesylate, STI571) in Monotherapy Versus Glivec®-Interferon Alpha in the Treatment of Chronic-Phase Chronic Myeloid Leukaemia Completed NCT00390897 Phase 4
31 Intensified Conditioning Regimen With High-Dose-Etoposide for Allo-HSCT for Adult Acute Lymphoblastic Leukemia Completed NCT01457040 Phase 4
32 AML2003 - Standard-Therapy vs Intensified Therapy for Adult Acute Myeloid Leukemia Patients <= 60 Years Completed NCT00180102 Phase 4
33 Treatment of Newly Diagnosed Patients With Acute Promyelocytic Leukemia (PETHEMA LPA 2005) Completed NCT00408278 Phase 4
34 PETHEMA LAL-RI/96: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia Completed NCT00494897 Phase 4
35 Rituximab Plus Chemotherapy for CD20+ Adult Acute Lymphoblastic Leukemia Completed NCT01358253 Phase 4
36 Antiviral Treatment of Chronic Lymphocytic Leukemia Completed NCT01255644 Phase 4
37 Study of Oral AMN107 (Nilotinib) in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Previously Enrolled to CAMN107A2109 Trial Completed NCT01368523 Phase 4
38 A Study of Rituximab in Combination With Fludarabine and Cyclophosphamide in Participants With Chronic Lymphocytic Leukemia and Favorable Somatic Status Completed NCT01271010 Phase 4
39 LAL-AR-N-2005:Study Treatment for Children High Risk Acute Lymphoblastic Leukemia Completed NCT00526409 Phase 4
40 Study of Molecular Response in Adult Patients on Nilotinib With Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (Ph+ CML) in Chronic Phase and a Suboptimal Molecular Response to Imatinib Completed NCT00644878 Phase 4
41 A Study to Compare Mabthera (Rituximab), Fludarabine and Cyclophosphamide to Mabthera and Chlorambucil in Patients With Chronic Lymphocytic Leukemia and Unfavourable Somatic Status Completed NCT01283386 Phase 4
42 LAL-Ph-2000: Treatment of Acute Lymphoblastic Leukemia Chromosome Philadelphia Positive Completed NCT00526305 Phase 4
43 A Study to Confirm the Efficacy and Safety of Fludarabine Phosphate Administered in Untreated Chronic Lymphocytic Leukemia Patients With Anemia and/or Thrombocytopenia Completed NCT00220311 Phase 4
44 Treatment of Acute Myeloblastic Leukemia in Younger Patients Completed NCT00390715 Phase 4
45 SMD_FLAG-IDA_98: FLAG-IDA in Induction Treatment of High Risk Myelodysplastic Syndromes or Secondary Acute Myeloblastic Leukemia Completed NCT00487448 Phase 4
46 Study of Treatment With Nilotinib in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Completed NCT00786812 Phase 4
47 ALL-REZ BFM 2002: Multi-Center Study for Children With Relapsed Acute Lymphoblastic Leukemia Completed NCT00114348 Phase 4
48 Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib Completed NCT01660906 Phase 4
49 AML96 - Risk-Adapted and Randomized Postremission-Therapy for Adult Acute Myeloid Leukemia Patients Completed NCT00180115 Phase 4
50 Efficacy and Safety of Ofatumumab Retreatment and Maintenance Treatment in Patients With B-cell Chronic Lymphocytic Leukemia (CLL) Completed NCT00802737 Phase 4

Search NIH Clinical Center for Leukemia

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Leukemia cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: leukemia

Genetic Tests for Leukemia

Genetic tests related to Leukemia:

id Genetic test Affiliating Genes
1 Leukemia 29

Anatomical Context for Leukemia

MalaCards organs/tissues related to Leukemia:

39
Myeloid, T Cells, B Cells, Bone, Bone Marrow, Monocytes, Neutrophil

Publications for Leukemia

Articles related to Leukemia:

(show top 50) (show all 27705)
id Title Authors Year
1
Long-term persistent donor-recipient mixed chimerism without disease recurrence after myeloablative single-unit cord blood transplantation in adult acute myeloid leukemia following myelodysplastic syndrome. ( 28509586 )
2017
2
Association of ARID5B gene variants with acute lymphoblastic leukemia in Yemeni children. ( 28381164 )
2017
3
Infectious complications in chronic lymphocytic leukemia- a retrospective analysis: single institution experience. ( 28503927 )
2017
4
Phase I Trial of Total Marrow and Lymphoid Irradiation Transplant Conditioning in Patients with Relapsed/Refractory Acute Leukemia. ( 28087456 )
2017
5
Neutropenic acute acalculous cholecystitis (AAC) in a 12-year-old boy with T-acute lymphoblastic leukemia successfully managed with conservative treatment. ( 28085529 )
2017
6
Acute myelitis resembling human T-lymphotropic virus type 1-associated myelopathy presenting as high-signal-intensity long cord lesions on T2-weighted magnetic resonance images combined with lymphoma-type adult T-cell leukemia/lymphoma. ( 27817856 )
2017
7
Ibrutinib Therapy Increases T Cell Repertoire Diversity in Patients with Chronic Lymphocytic Leukemia. ( 28077600 )
2017
8
Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association Group. ( 28056203 )
2017
9
Hematopoeitic stem cell transplantation for adult T cell leukemia-lymphoma: Who is the best candidate? ( 27786571 )
2017
10
Dismal outcome of allogeneic hematopoietic stem cell transplantation for relapsed adult T-cell leukemia/lymphoma, a Japanese nation-wide study. ( 28067877 )
2017
11
Utility of the serum galactomannan assay for the diagnosis of invasive aspergillosis in children with acute lymphoblastic leukemia. ( 27815226 )
2017
12
Linear nonpalpable purpura in a young male: a unique presentation of leukemia cutis in T-cell prolymphocytic leukemia. ( 28083939 )
2017
13
Unconventional oil and gas development and risk of childhood leukemia: Assessing the evidence. ( 27783932 )
2017
14
Major molecular response prior to allogeneic hematopoietic stem cell transplantation predicts better outcome in adult Philadelphia-positive acute lymphoblastic leukemia in first remission. ( 28092348 )
2017
15
State of the Art in MicroRNA as Diagnostic and Therapeutic Biomarkers in Chronic Lymphocytic Leukemia. ( 28084621 )
2017
16
Correction: Rapidly Progressing Myelodysplastic Syndrome Initially Presenting as Acute Leukemia. ( 28465876 )
2017
17
Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF-06747143) in chronic lymphocytic leukemia. ( 28526063 )
2017
18
Erratum to: "Reduced-Intensity Conditioning Combined with (188)Rhenium Radioimmunotherapy before Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia: The Role of in Vivo T Cell Depletion" [Biol Blood Marrow Transplant 2015;21:1754-1760]. ( 28068509 )
2017
19
Near-triploid B lymphoblastic leukemia with Burkitt-like morphology. ( 28082295 )
2017
20
Using Murine Models to Investigate Tumor-Lymphoid Interactions: Spotlight on Chronic Lymphocytic Leukemia and Angioimmunoblastic T-Cell Lymphoma. ( 28512625 )
2017
21
Treatment of chronic lymphocytic leukemia in older adults. ( 28487078 )
2017
22
Dancing partners at the ball: Rational selection of next generation anti-CD20 antibodies for combination therapy of chronic lymphocytic leukemia in the novel agents era. ( 28499646 )
2017
23
Low dose of 2-deoxy-D-glucose kills acute lymphoblastic leukemia cells and reverses glucocorticoid resistance via N-linked glycosylation inhibition under normoxia. ( 28415682 )
2017
24
Risk of sinusoidal obstruction syndrome in allogeneic stem cell transplantation after prior gemtuzumab ozogamicin treatment: a retrospective study from the Acute Leukemia Working Party of the EBMT. ( 28092357 )
2017
25
Genome-wide study links PNPLA3 variant with elevated hepatic transaminase after acute lymphoblastic leukemia therapy. ( 28090653 )
2017
26
Plasma matrix metalloprotease 9 correlates with blood lymphocytosis, leukemic cell invasiveness, and prognosis in B-cell chronic lymphocytic leukemia. ( 28240053 )
2017
27
Survival Outcome of Filipino Children With Acute Lymphoblastic Leukemia Treated With Modified Berlin-Frankfurt-Muenster/Hong Kong Acute Lymphoblastic Leukemia (BFM95/HKALL97) Protocol in a Tertiary General Hospital From January 2005 to December 2009: A Retrospective Cohort Study. ( 28085747 )
2017
28
BCR-ABL1-positive chronic myeloid leukemia emerging in a patient with secondary myelofibrosis harboring the JAK2-V617F mutation. ( 28484156 )
2017
29
Use of minimal residual disease assessment in the treatment of chronic lymphocytic leukemia. ( 28509580 )
2017
30
Plasma cell neoplasm with plasmablastic morphology mimicking acute leukemia. ( 28057674 )
2017
31
sIL2R ratio as early marker for response in hairy cell leukemia and the prognostic relevance of IL28B genotype to interferon-I+ therapy. ( 28214980 )
2017
32
Long noncoding RNA HULC promotes cell proliferation by regulating PI3K/AKT signaling pathway in chronic myeloid leukemia. ( 28069548 )
2017
33
The Expression of Toll-Like Receptors in Patients with B-Cell Chronic Lymphocytic Leukemia. ( 28083607 )
2017
34
Downregulation of miR-451 in Tunisian chronic myeloid leukemia patients: potential implication in imatinib resistance. ( 27825294 )
2017
35
Obinutuzumab is Effective in Chronic Lymphocytic Leukemia and Rheumatoid Arthritis After Rituximab Failure: A Case Report. ( 28487504 )
2017
36
Response of renal cell carcinoma to ibrutinib, a bruton tyrosine kinase inhibitor, in a patient treated for chronic lymphocytic leukemia. ( 28503240 )
2017
37
Meis1 is critical to the maintenance of human acute myeloid leukemia cells independent of MLL rearrangements. ( 28054140 )
2017
38
Tyrosine Kinase Inhibitor for Treatment of Adult Allogeneic Hematopoietic Stem Cell Transplantation Candidate with Philadelphia-Positive Acute Lymphoblastic Leukemia. ( 28091401 )
2017
39
Establishment of mouse leukemia cell lines expressing human CD4/CCR5 using lentiviral vectors. ( 28028680 )
2017
40
Histone deacetylase inhibitors in plasma cell leukemia treatment: Effect of bone marrow microenvironment. ( 28043150 )
2017
41
Prognostic Impact of Specific Molecular Profiles in Pediatric Acute Megakaryoblastic Leukemia in Non-Down Syndrome. ( 28063190 )
2017
42
Clinical impact of galectin-3 in newly diagnosed t (15;17)(q22;q21)/PML-RARa acute promyelocytic leukemia treated with all-trans retinoic acid and arsenic trioxide-based regimens. ( 28238096 )
2017
43
Dual SYK/JAK inhibition overcomes ibrutinib resistance in chronic lymphocytic leukemia: Cerdulatinib, but not ibrutinib, induces apoptosis of tumor cells protected by the microenvironment. ( 28088788 )
2017
44
Trends in childhood leukemia incidence over two decades from 1992 to 2013. ( 27778348 )
2017
45
Concordance of two approaches in monitoring of minimal residual disease in B-precursor acute lymphoblastic leukemia: Fusion transcripts and leukemia-associated immunophenotypes. ( 28063722 )
2017
46
ATP-binding casette transporter expression in acute myeloid leukemia: association with in vitro cytotoxicity and prognostic markers. ( 28112576 )
2017
47
Indirect Treatment Comparisons of Ibrutinib Versus Physician's Choice and Idelalisib Plus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia. ( 28062113 )
2017
48
Oncogenic ZEB2 activation drives sensitivity towards KDM1A inhibition in T-cell acute lymphoblastic leukemia. ( 28069602 )
2017
49
Influence of CYP2C8 polymorphisms on imatinib steady-state trough level in chronic myeloid leukemia and gastrointestinal stromal tumor patients. ( 28383355 )
2017
50
Targeting BET proteins improves the therapeutic efficacy of BCL-2 inhibition in T-cell acute lymphoblastic leukemia. ( 28074072 )
2017